title: Thrombosis during pregnancy: Risks, prevention, and treatment for mother and fetus--harvesting the power of omic technology, biomarkers and in vitro or in vivo models to facilitate the treatment of thrombosis.
abstract: Maternal thromboembolism and a spectrum of placenta-mediated complications including the pre-eclampsia syndromes, fetal growth restriction, fetal loss, and abruption manifest a shared etiopathogenesis and predisposing risk factors. Furthermore, these maternal and fetal complications are often linked to subsequent maternal health consequences that comprise the metabolic syndrome, namely, thromboembolism, chronic hypertension, and type II diabetes. Traditionally, several lines of evidence have linked vasoconstriction, excessive thrombosis and inflammation, and impaired trophoblast invasion at the uteroplacental interface as hallmark features of the placental complications. "Omic" technologies and biomarker development have been largely based upon advances in vascular biology, improved understanding of the molecular basis and biochemical pathways responsible for the clinically relevant diseases, and increasingly robust large cohort and/or registry based studies. Advances in understanding of innate and adaptive immunity appear to play an important role in several pregnancy complications. Strategies aimed at improving prediction of these pregnancy complications are often incorporating hemodynamic blood flow data using non-invasive imaging technologies of the utero-placental and maternal circulations early in pregnancy. Some evidence suggests that a multiple marker approach will yield the best performing prediction tools, which may then in turn offer the possibility of early intervention to prevent or ameliorate these pregnancy complications. Prediction of maternal cardiovascular and non-cardiovascular consequences following pregnancy represents an important area of future research, which may have significant public health consequences not only for cardiovascular disease, but also for a variety of other disorders, such as autoimmune and neurodegenerative diseases.
authors.affiliation: Department of Obstetrics and Gynecology, University of Milan-Bicocca, Monza, Italy.|Department of Obstetrics, Gynecology and Reproductive Sciences, Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Sara
authors.initials: S
authors.lastname: Ornaghi
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement, Yale University School of Medicine, New Haven, Connecticut.|Department of Obstetrics and Gynecology, University Hospital Bern, Bern, Switzerland.
authors.forename: Martin
authors.initials: M
authors.lastname: Mueller
authors.affiliation: Society for the Investigation of Early Pregnancy, Cherry Hill, New Jersey.|BioIncept LLC, Cherry Hill, New Jersey.
authors.forename: Eytan R
authors.initials: ER
authors.lastname: Barnea
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Paidas
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D005260:Female; D023281:Genomics; D006801:Humans; D055432:Metabolomics; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000517:prevention & control / Q000628:therapy*; D040901:Proteomics; D012307:Risk Factors; D013927:Thrombosis / Q000517:prevention & control / Q000628:therapy*
chemical_list: D015415:Biomarkers
keywords: biomarkers; embryo signaling; omics; pregnancy; thrombosis